Status:
COMPLETED
A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Conditions:
Hemodialysis
Hyperphosphatemia
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the safety and efficacy when administering PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.
Eligibility Criteria
Inclusion
- Receiving stable maintenance hemodialysis 3 times a week
- Dialysis patients with hyperphosphatemia
Exclusion
- Patients having history of a pronounced brain / cardiovascular disorder
- Patients having severe gastrointestinal disorders
- Patients having severe hepatic disorders
Key Trial Info
Start Date :
April 29 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 3 2013
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01850641
Start Date
April 29 2013
End Date
December 3 2013
Last Update
October 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Japan